The Duke Comprehensive Cancer Center

The Duke Comprehensive Cancer Center (DCCC), established in 1973 by the national Cancer institute (NCI) as one of the original eight comprehensive cancer centers, is one of only 39 NCI-recognized comprehensive cancer centers nationwide today.

• The Duke Comprehensive Cancer Center leverages Duke’s basic research infrastructure with a unique focus on clinical oncology research excellence.
• The Cancer Center is supported by 16 shared resources and comprised of 11 research programs.
• Duke’s clinical oncology research is further enhanced by the presence of national clinical research resources including two NCI-funded cooperative groups, the Cancer and Leukemia Group B (CALGB) and the American College of Surgeons Oncology Group (ACOSOG).
• The Cancer Center has over 350 faculty and investigator members and is awarded more than $256 million annually in peer-reviewed funding.
• The National Cancer Institute has awarded the Cancer Center two prestigious Specialized Program of Research Excellence (SPORE) grants for its commitment to finding new and innovative ways to treat and prevent breast cancer and brain tumors.
• The Duke Comprehensive Cancer Center has teamed with the FDA, the National Cancer Institute, the American Society of Clinical Oncology, and the American Association of Cancer Research to host the annual Accelerating Anticancer Agent Development and Validation Workshop aimed at expediting the development and validation process for new cancer treatments so that they can be made available to patients sooner.